Stock 24H HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

News Hansa Biopharma AB Börse Stuttgart

Equities

24H

SE0002148817

Delayed Börse Stuttgart
Other stock markets
 13:00:45 28/06/2024 BST 		5-day change 1st Jan Change
4.132 EUR +2.28% Intraday chart for Hansa Biopharma AB +11.54% +72.35%
06-27 Hansa Biopharma AB Announces Board Appointments CI
05-31 Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hansa Biopharma: increase in number of shares and votes
AQ
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
AQ
Hansa Biopharma AB Announces Board Appointments
CI
Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm
AQ
Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial
MT
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
AQ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial
CI
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
AQ
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
AQ
Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting
CI
Correction, Hansa Biopharma, increase in number of shares and votes
AQ
Correction: Hansa Biopharma: increase in number of shares and votes
PU
Hansa Biopharma: increase in number of shares and votes
AQ
Hansa Biopharma Q1 - Improved European launch support
AQ
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue
MT
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. 24H Stock
  5. News Hansa Biopharma AB